 | Up a level |
Rothermundt, Christian; Andreou, Dimosthenis; Blay, Jean-Yves; Brodowicz, Thomas; Desar, Ingrid M E; Dileo, Palma; Gelderblom, Hans; Haas, Rick; Jakob, Jens; Jones, Robin L; Judson, Ian; Kunz, Wolfgang G; Liegl-Atzwanger, Berndadette; Lindner, Lars H; Messiou, Christina; Miah, Aisha B; Reichardt, Peter; Szkandera, Joanna; van der Graaf, Winette T A; van Houdt, Winan J; ... (2023). Controversies in the management of patients with soft tissue sarcoma: Recommendations of the Conference on State of Science in Sarcoma 2022. European journal of cancer, 180, pp. 158-179. Elsevier 10.1016/j.ejca.2022.11.008
Issels, Rolf D; Noessner, Elfriede; Lindner, Lars H; Schmidt, Michael; Albertsmeier, Markus; Blay, Jean-Yves; Stutz, Emanuel; Xu, Yujun; Buecklein, Veit; Altendorf-Hofmann, Annelore; Abdel-Rahman, Sultan; Mansmann, Ulrich; von Bergwelt-Baildon, Michael; Knoesel, Thomas (2021). Immune infiltrates in patients with localised high-risk soft tissue sarcoma treated with neoadjuvant chemotherapy without or with regional hyperthermia: A translational research program of the EORTC 62961-ESHO 95 randomised clinical trial. European journal of cancer, 158, pp. 123-132. Elsevier 10.1016/j.ejca.2021.09.015
Rothermundt, Christian; Fischer, Galina F; Bauer, Sebastian; Blay, Jean-Yves; Grünwald, Viktor; Italiano, Antoine; Kasper, Bernd; Kollár, Attila; Lindner, Lars H; Miah, Aisha; Sleijfer, Stefan; Stacchiotti, Silvia; Putora, Paul Martin (2018). Pre- and Postoperative Chemotherapy in Localized Extremity Soft Tissue Sarcoma: A European Organization for Research and Treatment of Cancer Expert Survey. Oncologist, 23(4), pp. 461-467. AlphaMed Press 10.1634/theoncologist.2017-0391
Gao, Shan; Bajrami, Ilirjana; Verrill, Clare; Kigozi, Asha; Ouaret, Djamila; Aleksic, Tamara; Asher, Ruth; Han, Cheng; Allen, Paul; Bailey, Deborah; Feller, Stephan; Kashima, Takeshi; Athanasou, Nicholas; Blay, Jean-Yves; Schmitz, Sandra; Machiels, Jean-Pascal; Upile, Nav; Jones, Terry M; Thalmann, George; Ashraf, Shazad Q; ... (2014). Dsh homolog DVL3 mediates resistance to IGFIR inhibition by regulating IGF-RAS signaling. Cancer research, 74(20), pp. 5866-5877. American Association for Cancer Research AACR 10.1158/0008-5472.CAN-14-0806
